Amyloid beta-peptide possesses a transforming growth factor-beta activity

Area of Science:

• Neuroscience
• Molecular Biology
• Biochemistry

Background:

• Alzheimer's disease (AD) is characterized by amyloid beta-peptide (Abeta) plaques, which contribute to neuronal damage.
• Abeta aggregates are implicated in neuroinflammation and dysfunction.
• Transforming growth factor-beta (TGF-beta) plays a role in neurodegeneration and is present in AD plaques.

Purpose of the Study:

• To investigate the hypothesis that Abeta monomers and aggregates function as TGF-beta antagonists and partial agonists.
• To explore the role of the FAED motif in Abeta's interaction with TGF-beta receptors.
• To assess the biological activities of Abeta and its analogues on TGF-beta signaling and cell viability.

Main Methods:

• Inhibition of radiolabeled TGF-beta binding to TGF-beta receptors in Mv1Lu cells.
• Assessment of cytotoxicity of Abeta-(1-40)-bovine serum albumin conjugate (Abeta-(1-40)-BSA) on endothelial and neuronal cells.
• Measurement of TGF-beta-induced plasminogen activator inhibitor-1 expression.
• Evaluation of Abeta-(1-40)-BSA and Abeta-(1-40) monomer effects on Mv1Lu cell proliferation.

Main Results:

• Abeta monomers, Abeta-(1-40), and a fragment containing the FAED motif inhibited TGF-beta binding to receptors.
• A multivalent Abeta-(1-40)-BSA conjugate was 100-670 times more potent than Abeta-(1-40) monomers in inhibiting TGF-beta binding and TGF-beta-induced PAI-1 expression.
• Abeta-(1-40)-BSA, but not monomers, inhibited Mv1Lu cell proliferation at micromolar concentrations.
• Abeta-(1-40)-BSA exhibited cytotoxicity towards endothelial and neuronal cells.

Conclusions:

• Abeta monomers and aggregates function as TGF-beta antagonists and partial agonists.
• The multivalent nature of Abeta aggregates significantly enhances their potency in modulating TGF-beta signaling.
• These TGF-beta antagonistic/agonistic activities of Abeta may contribute to the pathogenesis of Alzheimer's disease.